Ming-Chu Hsu

USPTO Granted Patents = 11 (Patent Applications = 2)

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 4.5

ph-index = 3

Forward Citations = 23(Granted Patents)

Location History:

Glendora, CA (US) (2004 - 2018)
Taipei, TW (2005 - 2018)
Santa Clara, CA (US) (2019 - 2020)

Company Filing History:

6 out of 16

Taigen Biotechnology Company, Ltd.

patents

4 out of 181

National Health Research Institutes

patents

1 out of 55

Teco Image Systems Co., Ltd.

patents

Years Active: 2004-2020

where 'Filed Patents' based on already Granted Patents

11 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10596171 - Cap-dependent endonuclease inhibitors (2020-03-24),

2. 10377714 - Trans-isomeric heterocyclic compounds and preparation thereof (2019-08-13),

3. 10004719 - Solid dispersion formulation (2018-06-26),

4. 9871931 - Scanner capable of executing static calibration and compensation value adjustment method therefor (2018-01-16),

5. 9375406 - Substituted pyrimidines for mobilizing cells expressing a type 4 CXC chemokine receptor (2016-06-28),

6. 8211909 - Treatment of antibiotic-resistant bacteria infection (2012-07-03),

7. 7662834 - Methods of 1H-indol-3-yl-2-oxoacetamide compounds (2010-02-16),

8. 7462594 - Peptide-like compounds that inhibit coronaviral 3CL and flaviviridae viral proteases (2008-12-09),

9. 7396838 - Use of 1H-indol-3-yl-2-oxoacetamide compounds (2008-07-08),

10. 6903104 - Indol-3-YL-2-oxoacetamide compounds and methods of use thereof (2005-06-07),

11. 6706739 - Imidazolidinone compounds (2004-03-16),

Title: The Innovative Contributions of Ming-Chu Hsu

Introduction

Ming-Chu Hsu is a prominent inventor based in Glendora, California. He has made significant contributions to the field of biotechnology, holding a total of 11 patents. His work primarily focuses on developing compounds that have therapeutic applications, particularly in treating viral infections.

Latest Patents

Among his latest patents is a compound designed as a cap-dependent endonuclease inhibitor. This compound, represented by a specific formula, includes various chemical groups that can be modified for enhanced efficacy. The invention also outlines a method for using this compound in treating influenza, along with a pharmaceutical composition that incorporates it. Another notable patent involves trans-isomeric heterocyclic compounds, which are characterized by a specific trans:cis ratio. This patent also details a method for preparing these compounds, showcasing Hsu's innovative approach to drug development.

Career Highlights

Ming-Chu Hsu has worked with several reputable organizations throughout his career. He has been associated with Taigen Biotechnology Company, Ltd. and the National Health Research Institutes. His experience in these institutions has allowed him to advance his research and contribute to significant scientific advancements.

Collaborations

Hsu has collaborated with notable colleagues, including Chu-Chung Lin and Shu-Jen Chen. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his work in the field.

Conclusion

Ming-Chu Hsu's innovative contributions to biotechnology and his extensive patent portfolio underscore his role as a leading inventor in his field. His work continues to influence the development of new therapeutic agents, particularly in the fight against viral infections.

This text is generated by artificial intelligence and may not be accurate.